Product & Industry News
Drug Discovery World
UK secures portfolio of promising vaccines candidates from BioNTech/Pfizer alliance

UK secures portfolio of promising vaccines candidates from BioNTech/Pfizer alliance

20 July 2020
Image: Marcus Winkler

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising Covid-19 vaccine candidates.

The UK government has agreed significant partnerships with leading pharmaceutical and vaccine companies BioNTech/Pfizer and Valneva that are developing new vaccines to protect people against Covid-19. The government has also secured access to treatments containing Covid-19-neutralising antibodies from AstraZeneca to protect those who cannot receive vaccines such as cancer and immunocompromised patients.

As a result of these partnerships, England, Scotland, Wales and Northern Ireland could have access to enough doses to vaccinate and protect priority groups identified, such as frontline health and social care workers and those at increased health risk.

UK Business Secretary, Alok Sharma, said: “The hunt to find a vaccine is a truly global endeavour and we are doing everything we can to ensure the British public get access to a safe and effective coronavirus vaccine as soon as possible.

“This new partnership with some of the world’s foremost pharmaceutical and vaccine companies will ensure the UK has the best chance possible of securing a vaccine that protects those most at risk.”

Through its partnership with Valneva, which has a factory in Livingston, Scotland, the UK government is expected to contribute to UK clinical studies costs and is negotiating funding to expand Valneva’s Scottish facility. This increased manufacturing capacity could potentially supply up to 100 million vaccine doses to the UK and internationally. This will create high-skilled jobs in the local area and contribute significantly to the local economy.

The Livingston facility is in addition to the new Vaccines Manufacturing and Innovation Centre (VMIC) which is currently under construction in Oxfordshire thanks to a £93 million investment from the UK government. When completed in summer 2021, the facility will have flexible capacity to manufacture vaccine doses at scale.

Chair of the Vaccine Taskforce Kate Bingham said: “The Vaccine Taskforce is investing in a diverse portfolio of vaccine candidates to maximise the chances of finding a vaccine quickly that meets the UK’s rigorous regulatory and safety standards. The fact that we have so many promising candidates already shows the unprecedented pace at which we are moving. But I urge against being complacent or over optimistic. The fact remains we may never get a vaccine and if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms.”

More on this subject...
Drug Discovery World

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate READ MORE

Drug Discovery World

Insect-based technology for human vaccines READ MORE

Drug Discovery World

Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate READ MORE

Drug Discovery World

Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe READ MORE

Drug Discovery World

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago READ MORE

Drug Discovery World

Symbiosis to manufacture COVID-19 vaccine for clinical trials READ MORE

Drug Discovery World

Avacta positive on evaluation of COVID-19 test strips READ MORE

Drug Discovery World

PrecisionLife identifies 68 genes associated with risk of severe COVID-19 READ MORE

Drug Discovery World

Imaging system produces human cellular morphological data for COVID-19 research READ MORE

Drug Discovery World

MMR vaccination might protect children from COVID-19 READ MORE